First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of
actions that influence homeostatic mechanisms throughout the body. Two receptor subtypes …

Endothelin-1 (ET-1) is a major regulator of vascular function, acting via both endothelin
receptor type A (ETAR) and type B (ETBR). Although the role of ETAR in vascular smooth …

Endothelin receptor antagonists (ERAs) have been developed to block the effects of
endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful …

Rationale: Endothelin-1 (ET1) is dysregulated in pulmonary hypertension (PH). It may be
important in the pathobiology of congenital diaphragmatic hernia (CDH). Objectives: We …

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasoproliferative
disorder characterized by the development of unique neointimal lesions, including …

Background Plasma endothelin and adrenomedullin are increased in patients with
pulmonary arterial hypertension, hypoxia, and pulmonary infections, conditions that predict …

Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system,
which leads to right-sided heart failure and ultimately death if untreated. Treatments to …

Abstract Endothelin-1 (ET-1) is a 21-amino acid polypeptide produced primarily by vascular
endothelial cells. First discovered in 1988 as a potent vasoconstrictor, it has subsequently …

Congenital diaphragmatic hernia (CDH) is a major cause of refractory respiratory failure in
the neonatal period and is characterized by persistent pulmonary hypertension of the …

BACKGROUND: Endothelin-1 (ET-1), a potent vasoconstrictor, is considered to be
implicated in failing Fontan circulation, however the expressions of ET-1 and endothelin …